· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Атмосфера. Новости кардиологии 2012 / N 1 Актуальные проблемы фармакотерапии хронической сердечной недостаточности (окончание) (список литературы) Е.В. Резник, Г.Е. Гендлин, Г.И. Сторожаков Cписок литературы 1. Даниелян МО, Прогноз и лечение хронической сердечной недостаточности (данные 20–и летнего наблюдения). Автореф. дис. канд. мед. наук. 2001. 2. Мареев ВЮ, Агеев ФТ, Арутюнов ГП, Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). // Сердечная недостаточность, 2007. T. 39. № 1. С. 4-41. 3. Мареев ВЮ, Агеев ФТ, Арутюнов ГП et al., Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). // Сердечная недостаточность, 2009. T. 10. № 2. С. 64-103. 4. Резник ЕВ, Почки как орган-мишень при хронической сердечной недостаточности: Lamber, 2011. 188 с. 5. Резник ЕВ, Гендлин ГЕ, Гущина ВМ et al., Хроническая болезнь почек у больных с хронической середчной недостаточностью (Обзор литературы). // Нефрология и диализ, 2010. T. 12. № 1. С. 13-24. 6. Резник ЕВ, Гендлин ГЕ, Хрипун АИ et al., Функциональное состояние почек, экскреция альбумина с мочой и почечная гемодинамика у больных с хронической сердечной недостаточностью. // Нефрология и диализ, 2010. T. 12. № 4. С. 275-286. 7. Сторожаков ГИ, Резник ЕВ, Эволюция Национальных рекомендаций по диагностике и лечению ХСН ВНОК/ОССН с 2006 по 2009г. и их сравнительный анализ с международными рекомендациями ESС и АСС/АНА. // Атмосфера. Новости кардиологии. Журнал для практикующих врачей, 2009 № 1. С. 10-16. 8. Фомин ИВ, Беленков ЮН, Мареев ВЮ, Распространенность ХСН в Европей-ской части Российской Федерации - данные ЭПОХА-ХСН. // Сердечная недостаточность, 2006. T. 7. № 1(35). С. 4-8. 9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. //N Engl J Med 1991. Vol. 325 (5): P. 293-302. 10. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. //N Engl J Med 1997. Vol. 336 (8): P. 525-33. 11. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. //Eur Heart J 1998. Vol. 19 (3): P. 481-9. 12. Abraham WT, Aranda JM, Boehmer JP et al., Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. //Clin Transl Sci 2010. Vol. 3 (5): P. 249-53. 13. Anker SD, Comin Colet J, Filippatos G et al., Ferric carboxymaltose in patients with heart failure and iron deficiency. //N Engl J Med 2009. Vol. 361 (25): P. 2436-48. 14. Bakris GL, Weir MR, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? //Arch Intern Med 2000. Vol. 160 (5): P. 685-93. 15. Bellomo R, Ronco C, The kidney in heart failure. //Kidney Int Suppl 1998. Vol. 66: P. S58-61. 16. Bohm M, Swedberg K, Komajda M et al., Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. //Lancet 2010. Vol. 376 (9744): P. 886-94. 17. Borlaug BA, Paulus WJ, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. //Eur Heart J 2011. Vol. 32 (6): P. 670-9. 18. Bristow MR, Gilbert EM, Abraham WT et al., Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. //Circulation 1996. Vol. 94 (11): P. 2807-16. 19. Brophy JM, Joseph L, Rouleau JL, Beta-blockers in congestive heart failure. A Bayesian meta-analysis. //Ann Intern Med 2001. Vol. 134 (7): P. 550-60. 20. Butler J, Forman DE, Abraham WT et al., Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. //Am Heart J 2004. Vol. 147 (2): P. 331-8. 21. Cleland JG, Freemantle N, Coletta AP et al., Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. //Eur J Heart Fail 2006. Vol. 8 (1): P. 105-10. 22. Cleland JG, Tendera M, Adamus J et al., The perindopril in elderly people with chronic heart failure (PEP-CHF) study. //Eur Heart J 2006. Vol. 27 (19): P. 2338-45. 23. Cohn JN, Tognoni G, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. //N Engl J Med 2001. Vol. 345 (23): P. 1667-75. 24. Costanzo MR, Saltzberg MT, Jessup M et al., Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. //J Card Fail 2010. Vol. 16 (4): P. 277-84. 25. Delles C, Schmieder RE, The kidney in congestive heart failure: renal adverse event rate of treatment. //J Cardiovasc Pharmacol 2001. Vol. 38 (1): P. 99-107. 26. Deswal A, Richardson P, Bozkurt B et al., Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). //J Card Fail 2011. Vol. 17 (8): P. 634-42. 27. Dickstein K, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Reply. //Eur Heart J 2008. 28. Dickstein K, Cardiac myosin activation: will theory and practice coincide? //Lancet 2011. Vol. 378 (9792): P. 639-41. 29. Dickstein K, Cohen-Solal A, Filippatos G et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). //Eur J Heart Fail 2008. Vol. 10 (10): P. 933-89. 30. Dickstein K, Kjekshus J, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. //Lancet 2002. Vol. 360 (9335): P. 752-60. 31. Dickstein K, Vardas PE, Auricchio A et al., 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. //Eur Heart J 2010. Vol. 31 (21): P. 2677-87. 32. Frances CD, Noguchi H, Massie BM et al., Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. //Arch Intern Med 2000. Vol. 160 (17): P. 2645-50. 33. From AM, Borlaug BA, Heart failure with preserved ejection fraction: pathophysiology and emerging therapies. //Cardiovasc Ther 2011. Vol. 29 (4): P. e6-21. 34. Fukuta H, Sane DC, Brucks S et al., Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. //Circulation 2005. Vol. 112 (3): P. 357-63. 35. Gheorghiade M, Albaghdadi M, Zannad F et al., Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). //Eur J Heart Fail 2011. Vol. 13 (1): P. 100-6. 36. Gheorghiade M, Blair JE, Filippatos GS et al., Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. //J Am Coll Cardiol 2008. Vol. 51 (23): P. 2276-85. 37. Gheorghiade M, Gattis WA, O'Connor CM et al., Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. //Jama 2004. Vol. 291 (16): P. 1963-71. 38. Gheorghiade M, Konstam MA, Burnett JC, Jr. et al., Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. //Jama 2007. Vol. 297 (12): P. 1332-43. 39. Gottlieb SS, Renal effects of adenosine A1-receptor antagonists in congestive heart failure. //Drugs 2001. Vol. 61 (10): P. 1387-93. 40. Gottlieb SS, Adenosine A1 antagonists and the cardiorenal syndrome. //Curr Heart Fail Rep 2008. Vol. 5 (2): P. 105-9. 41. Gottlieb SS, Abraham W, Butler J et al., The prognostic importance of different definitions of worsening renal function in congestive heart failure. //J Card Fail 2002. Vol. 8 (3): P. 136-41. 42. Granger CB, McMurray JJ, Yusuf S et al., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. //Lancet 2003. Vol. 362 (9386): P. 772-6. 43. Gu J, Noe A, Chandra P et al., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). //J Clin Pharmacol 2010. Vol. 50 (4): P. 401-14. 44. Hasenfuss G, Teerlink JR, Cardiac inotropes: current agents and future directions. //Eur Heart J 2011. Vol. 32 (15): P. 1838-45. 45. Hillege HL, Nitsch D, Pfeffer MA et al., Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. //Circulation 2006. Vol. 113 (5): P. 671-8. 46. Hood WB, Jr., Dans AL, Guyatt GH et al., Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. //J Card Fail 2004. Vol. 10 (2): P. 155-64. 47. Horwich TB, Fonarow GC, Hamilton MA et al., Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. //J Am Coll Cardiol 2002. Vol. 39 (11): P. 1780-6. 48. Hunt SA, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). //J Am Coll Cardiol 2005. Vol. 46 (6): P. e1-82. 49. Hunt SA, Abraham WT, Chin MH et al., 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. //J Am Coll Cardiol 2009. Vol. 53 (15): P. e1-e90. 50. Hunt SA, Abraham WT, Chin MH et al., 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. //Circulation 2009. Vol. 119 (14): P. e391-479. 51. Hunt SA, Abraham WT, Chin MH et al., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. //Circulation 2005. Vol. 112 (12): P. e154-235. 52. Jabbour A, Macdonald PS, Keogh AM et al., Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. //J Am Coll Cardiol 2010. Vol. 55 (17): P. 1780-7. 53. Jankowska EA, Rozentryt P, Witkowska A et al., Iron deficiency: an ominous sign in patients with systolic chronic heart failure. //Eur Heart J 2010. Vol. 31 (15): P. 1872-80. 54. Jessup M, Abraham WT, Casey DE et al., 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. //Circulation 2009. Vol. 119 (14): P. 1977-2016. 55. Kittleson M, Hurwitz S, Shah MR et al., Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. //J Am Coll Cardiol 2003. Vol. 41 (11): P. 2029-35. 56. Komajda M, Lutiger B, Madeira H et al., Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). //Eur J Heart Fail 2004. Vol. 6 (4): P. 467-75. 57. Konstam MA, Gheorghiade M, Burnett JC, Jr. et al., Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. //Jama 2007. Vol. 297 (12): P. 1319-31. 58. Konstam MA, Neaton JD, Dickstein K et al., Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. //Lancet 2009. Vol. 374 (9704): P. 1840-8. 59. Krum H, Iyngkaran P, Lekawanvijit S, Pharmacologic management of the cardiorenal syndrome in heart failure. //Curr Heart Fail Rep 2009. Vol. 6 (2): P. 105-11. 60. Krum H, Jelinek MV, Stewart S et al., 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. //Med J Aust 2011. Vol. 194 (8): P. 405-9. 61. Krum H, Massie B, Abraham WT et al., Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. //Eur J Heart Fail 2011. Vol. 13 (1): P. 107-14. 62. Krum H, Teerlink JR, Medical therapy for chronic heart failure. //Lancet 2011. Vol. 378 (9792): P. 713-21. 63. Kuenzli A, Bucher HC, Anand I et al., Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. //PLoS One 2010. Vol. 5 (4): P. e9946. 64. Lakhdar R, Al-Mallah MH, Lanfear DE, Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. //J Card Fail 2008. Vol. 14 (3): P. 181-8. 65. Levitan EB, Wolk A, Mittleman MA, Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. //Eur Heart J 2009. Vol. 30 (12): P. 1495-500. 66. Licata G, Di Pasquale P, Parrinello G et al., Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. //Am Heart J 2003. Vol. 145 (3): P. 459-66. 67. Mahapatra HS, Lalmalsawma R, Singh NP et al., Cardiorenal syndrome. //Iran J Kidney Dis 2009. Vol. 3 (2): P. 61-70. 68. Malik FI, Hartman JJ, Elias KA et al., Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. //Science 2011. Vol. 331 (6023): P. 1439-43. 69. Marcus LS, Hart D, Packer M et al., Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. //Circulation 1996. Vol. 94 (12): P. 3184-9. 70. Massie BM, Carson PE, McMurray JJ et al., Irbesartan in patients with heart failure and preserved ejection fraction. //N Engl J Med 2008. Vol. 359 (23): P. 2456-67. 71. Maxwell AP, Ong HY, Nicholls DP, Influence of progressive renal dysfunction in chronic heart failure. //Eur J Heart Fail 2002. Vol. 4 (2): P. 125-30. 72. McAlister FA, Wiebe N, Ezekowitz JA et al., Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. //Ann Intern Med 2009. Vol. 150 (11): P. 784-94. 73. McKelvie RS, Moe GW, Cheung A et al., The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. //Can J Cardiol 2011. Vol. 27 (3): P. 319-38. 74. McMurray J, Swedberg K, Treatment of chronic heart failure: a comparison between the major guidelines. //Eur Heart J 2006. Vol. 27 (15): P. 1773-7. 75. McMurray JJ, Anand IS, Diaz R et al., Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. //Eur J Heart Fail 2009. Vol. 11 (8): P. 795-801. 76. McMurray JJ, Ostergren J, Swedberg K et al., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. //Lancet 2003. Vol. 362 (9386): P. 767-71. 77. McMurray JJ, Pitt B, Latini R et al., Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. //Circ Heart Fail 2008. Vol. 1 (1): P. 17-24. 78. Mebazaa A, Nieminen MS, Packer M et al., Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. //Jama 2007. Vol. 297 (17): P. 1883-91. 79. Metra M, Eichhorn E, Abraham WT et al., Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. //Eur Heart J 2009. Vol. 30 (24): P. 3015-26. 80. Morrissey RP, Czer L, Shah PK, Chronic heart failure: current evidence, challenges to therapy, and future directions. //Am J Cardiovasc Drugs 2011. Vol. 11 (3): P. 153-71. 81. Muller K, Gamba G, Jaquet F et al., Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. //Eur J Heart Fail 2003. Vol. 5 (6): P. 793-801. 82. Murray MD, Deer MM, Ferguson JA et al., Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. //Am J Med 2001. Vol. 111 (7): P. 513-20. 83. Nieminen MS, Cleland JG, Eha J et al., Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. //Eur J Heart Fail 2008. Vol. 10 (12): P. 1246-54. 84. Packer M, Califf RM, Konstam MA et al., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). //Circulation 2002. Vol. 106 (8): P. 920-6. 85. Packer M, Poole-Wilson PA, Armstrong PW et al., Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. //Circulation 1999. Vol. 100 (23): P. 2312-8. 86. Pfeffer MA, McMurray JJ, Velazquez EJ et al., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. //N Engl J Med 2003. Vol. 349 (20): P. 1893-906. 87. Pfeffer MA, Swedberg K, Granger CB et al., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. //Lancet 2003. Vol. 362 (9386): P. 759-66. 88. Phillips CO, Kashani A, Ko DK et al., Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. //Arch Intern Med 2007. Vol. 167 (18): P. 1930-6. 89. Pitt B, Anker SD, Bushinsky DA et al., Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. //Eur Heart J 2011. Vol. 32 (7): P. 820-8. 90. Pitt B, Poole-Wilson PA, Segal R et al., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. //Lancet 2000. Vol. 355 (9215): P. 1582-7. 91. Pitt B, Remme W, Zannad F et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. //N Engl J Med 2003. Vol. 348 (14): P. 1309-21. 92. Pitt B, Zannad F, Remme WJ et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. //N Engl J Med 1999. Vol. 341 (10): P. 709-17. 93. Pokhrel N, Maharjan N, Dhakal B et al., Cardiorenal syndrome: A literature review. //Exp Clin Cardiol 2008. Vol. 13 (4): P. 165-70. 94. Rathore SS, Wang Y, Krumholz HM, Sex-based differences in the effect of digoxin for the treatment of heart failure. //N Engl J Med 2002. Vol. 347 (18): P. 1403-11. 95. Ruilope LM, Dukat A, Bohm M et al., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. //Lancet 2010. Vol. 375 (9722): P. 1255-66. 96. Schrier RW, Masoumi A, Elhassan E, Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome. //Blood Purif 2009. Vol. 27 (1): P. 28-32. 97. Sheppard R, Panyon J, Pohwani AL et al., Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. //J Card Fail 2004. Vol. 10 (5): P. 380-3. 98. Shlipak MG, Pharmacotherapy for heart failure in patients with renal insufficiency. //Ann Intern Med 2003. Vol. 138 (11): P. 917-24. 99. Shlipak MG, Massie BM, The clinical challenge of cardiorenal syndrome. //Circulation 2004. Vol. 110 (12): P. 1514-7. 100. Solomon SD, Shin SH, Shah A et al., Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. //Eur Heart J 2011. Vol. 32 (10): P. 1227-34. 101. Swedberg K, Cleland J, Dargie H et al., Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. //Eur Heart J 2005. Vol. 26 (11): P. 1115-40. 102. Swedberg K, Komajda M, Bohm M et al., Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. //Lancet 2010. Vol. 376 (9744): P. 875-85. 103. Swedberg K, Komajda M, Bohm M et al., Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). //Eur J Heart Fail 2010. Vol. 12 (1): P. 75-81. 104. Torre-Amione G, Young JB, Colucci WS et al., Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. //J Am Coll Cardiol 2003. Vol. 42 (1): P. 140-7. 105. van Veldhuisen DJ, Cohen-Solal A, Bohm M et al., Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). //J Am Coll Cardiol 2009. Vol. 53 (23): P. 2150-8. 106. Wang DJ, Dowling TC, Meadows D et al., Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. //Circulation 2004. Vol. 110 (12): P. 1620-5. 107. Willenheimer R, van Veldhuisen DJ, Silke B et al., Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. //Circulation 2005. Vol. 112 (16): P. 2426-35. 108. Yancy CW, Krum H, Massie BM et al., Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. //Circ Heart Fail 2008. Vol. 1 (1): P. 9-16. 109. Yusuf S, Pfeffer MA, Swedberg K et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. //Lancet 2003. Vol. 362 (9386): P. 777-81. 110. Zannad F, McMurray JJ, Krum H et al., Eplerenone in patients with systolic heart failure and mild symptoms. //N Engl J Med 2011. Vol. 364 (1): P. 11-21. 111. Zhou J, Shi H, Zhang J et al., Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. //Eur J Heart Fail 2010. Vol. 12 (2): P. 181-5.    [ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]